Search results
Results from the WOW.Com Content Network
Animal testing for gene therapy began in 2007 with a 2009 breakthrough in squirrel monkeys suggesting an imminent gene therapy in humans. While progress in gene therapy for red-green color blindness has slowed since then, successful human trials are currently underway for achromatopsia, a different form of color vision deficiency.
Translational Genomics Research Institute; California. Clear Labs; Genetic Information Research Institute; Joint Genome Institute (U.S. Department of Energy) Salk Institute for Biological Studies; Illinois. Carl R. Woese Institute for Genomic Biology (University of Illinois, Urbana-Champaign) Maine. The Jackson Laboratory; Maryland. Howard ...
Jesse Gelsinger (June 18, 1981 – September 17, 1999) was the first person publicly identified as having died in a clinical trial for gene therapy. Gelsinger suffered from ornithine transcarbamylase deficiency , an X-linked genetic disease of the liver , the symptoms of which include an inability to metabolize ammonia – a byproduct of ...
Alipogene tiparvovec (Glybera): AAV-based treatment for lipoprotein lipase deficiency (no longer commercially available); Axicabtagene ciloleucel (Yescarta): treatment for large B-cell lymphoma [1]
The Center for Cell and Gene Therapy conducts research into numerous diseases, including but not limited to pediatric cancers, [5] [6] diabetes, [7] HIV, glioma [8] and cardiovascular disease. The center has laboratory space in both Baylor College of Medicine and Texas Children's Hospital, and clinical units in Texas Children's and Methodist ...
Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV).
As a result of pressure from HIV-infected men in the gay community, [citation needed] who demanded better access to clinical trials, the U.S. Congress passed the Health Omnibus Programs Extension Act of 1988 (Public Law 100-607) [2] which mandated the development of a database of AIDS Clinical Trials Information Services (ACTIS). [3]
Keith Martin is an ophthalmologist.. He is the inaugural Professor of Ophthalmology at the University of Cambridge and a specialist in the treatment of glaucoma.In 2013, Professor Martin's team tested a novel technique of bio-printing, using an ink jet to recreate layers of ganglion and glial cells from a rat's retina, a process that has been described as 'printing eyeballs'.